{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:48:51Z","timestamp":1780364931915,"version":"3.54.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.euroneuro.2022.01.008","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:17:23Z","timestamp":1644538643000},"page":"100-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study"],"prefix":"10.1016","volume":"56","author":[{"given":"Marco","family":"Calabr\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0276-7865","authenticated-orcid":false,"given":"Chiara","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Souery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Albani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Forloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8531-5623","authenticated-orcid":false,"given":"Panagiotis","family":"Ferentinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mendlewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"De Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Crisafulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2022.01.008_bib0001","article-title":"Pharmacogenetics Guidelines: overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines","volume":"11","author":"Abdullah-Koolmees","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.euroneuro.2022.01.008_bib0002","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0278-5846(02)00357-3","article-title":"Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam","volume":"27","author":"Aoshima","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0003","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41398-019-0511-9","article-title":"A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments","volume":"9","author":"Arranz","year":"2019","journal-title":"Transl Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2022.01.008_bib0004","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","article-title":"Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice","volume":"20","author":"Bartova","year":"2019","journal-title":"World J. Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2022.01.008_bib0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FPC.0000000000000173","article-title":"Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder","volume":"25","author":"Bishop","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"10.1016\/j.euroneuro.2022.01.008_bib0006","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S2215-0366(19)30303-7","article-title":"Optimal dosing of antidepressant drugs","volume":"6","author":"Burchi","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0007","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/03014460.2017.1378368","article-title":"Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula","volume":"45","author":"Carano","year":"2018","journal-title":"Ann. Hum. Biol."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0008","article-title":"Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence","author":"Cellini","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0009","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/bs.apha.2018.03.003","article-title":"Pharmacogenetics in Psychiatry","volume":"83","author":"Corponi","year":"2018","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0010","unstructured":"CPIC, 2021. PGx implementers who are using CPIC guidelines."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0011","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12695","article-title":"Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity","volume":"13","author":"Dalton","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.01.008_bib0012","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/acps.12870","article-title":"Clinical correlates of augmentation\/combination treatment strategies in major depressive disorder","volume":"137","author":"Dold","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0013","series-title":"Drug and Biological Development","author":"Evens","year":"2007"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.01.008_bib0014","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/YIC.0000000000000305","article-title":"Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment","volume":"35","author":"Fabbri","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.01.008_bib0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.9758\/cpn.2020.18.4.484","article-title":"How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: step by Step Strategic Approach","volume":"18","author":"Fabbri","year":"2020","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"8","key":"10.1016\/j.euroneuro.2022.01.008_bib0016","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.euroneuro.2018.05.009","article-title":"Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies","volume":"28","author":"Fabbri","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.01.008_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020604","article-title":"The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology","volume":"21","author":"Fatunde","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0018","first-page":"22","article-title":"SSRI Antidepressant Medications: adverse Effects and Tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2022.01.008_bib0019","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.euroneuro.2017.06.009","article-title":"Escitalopram plasma levels and antidepressant response","volume":"27","author":"Florio","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.01.008_bib0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/tpj.2015.70","article-title":"Interethnic variation of CYP2C19 alleles, \u2018predicted\u2019 phenotypes and \u2018measured\u2019 metabolic phenotypes across world populations","volume":"16","author":"Fricke-Galindo","year":"2016","journal-title":"Pharmacogenomics J."},{"issue":"3\u20134","key":"10.1016\/j.euroneuro.2022.01.008_bib0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1359-6446(05)03681-0","article-title":"Role of pharmacologically active metabolites in drug discovery and development","volume":"11","author":"Fura","year":"2006","journal-title":"Drug Discov Today"},{"issue":"7","key":"10.1016\/j.euroneuro.2022.01.008_bib0022","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome p450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem. Res. Toxicol."},{"issue":"9","key":"10.1016\/j.euroneuro.2022.01.008_bib0024","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamapsychiatry.2014.436","article-title":"Emergency department visits by adults for psychiatric medication adverse events","volume":"71","author":"Hampton","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0025","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fgene.2012.00206","article-title":"Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19","volume":"3","author":"Helsby","year":"2012","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/j.euroneuro.2022.01.008_bib0026","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.euroneuro.2022.01.008_bib0027","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S2215-0366(19)30221-4","article-title":"Which antidepressant doses are optimal?","volume":"6","author":"Hieronymus","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"14","key":"10.1016\/j.euroneuro.2022.01.008_bib0028","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2217\/pgs.12.141","article-title":"Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population","volume":"13","author":"Hu","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"03","key":"10.1016\/j.euroneuro.2022.01.008_bib0029","first-page":"90","article-title":"Matplotlib: a 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"IEEE Annals of the History of Computing"},{"issue":"2","key":"10.1016\/j.euroneuro.2022.01.008_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/tpj.2014.50","article-title":"Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases","volume":"15","author":"Karlsson","year":"2015","journal-title":"Pharmacogenomics J."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.01.008_bib0031","doi-asserted-by":"crossref","first-page":"409","DOI":"10.31887\/DCNS.2008.10.4\/kkelly","article-title":"Toward achieving optimal response: understanding and managing antidepressant side effects","volume":"10","author":"Kelly","year":"2008","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1744-859X-13-17","article-title":"Antidepressant treatment response is modulated by genetic and environmental factors and their interactions","volume":"13","author":"Kovacs","year":"2014","journal-title":"Ann Gen Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0033","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jpba.2017.07.011","article-title":"Confirmation of metabolites of the neuroleptic drug prothipendyl using human liver microsomes, specific CYP enzymes and authentic forensic samples-Benefit for routine drug testing","volume":"145","author":"Kramer","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/NDT.S145046","article-title":"Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings","volume":"14","author":"Maciel","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0036","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 Structure, Function and Clinical Significance: a Review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr. Drug Targets"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0037","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41398-021-01469-6","article-title":"Gene expression studies in Depression development and treatment: an overview of the underlying molecular mechanisms and biological processes to identify biomarkers","volume":"11","author":"Mariani","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0038","series-title":"Proceedings of the 9th Python in Science Conference","doi-asserted-by":"crossref","first-page":"51","DOI":"10.25080\/Majora-92bf1922-00a","article-title":"Data structures for statistical computing in python","author":"McKinney","year":"2010"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e328340bc5a","article-title":"CYP2C19 variation and citalopram response","volume":"21","author":"Mrazek","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"10.1016\/j.euroneuro.2022.01.008_bib0040","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013","volume":"65","author":"Mrazek","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0041","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12991-017-0140-8","article-title":"Smoking and antidepressants pharmacokinetics: a systematic review","volume":"16","author":"Oliveira","year":"2017","journal-title":"Ann Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0042","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","article-title":"Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe","volume":"28","author":"Petrovic","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"12","key":"10.1016\/j.euroneuro.2022.01.008_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.29411","article-title":"Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients","volume":"3","author":"Ramsey","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.euroneuro.2022.01.008_bib0044","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.15r10583","article-title":"Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies","volume":"78","author":"Rosenblat","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2022.01.008_bib0045","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2022.01.008_bib0046","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/cts.12451","article-title":"A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans","volume":"10","author":"Ryu","year":"2017","journal-title":"Clin Transl Sci"},{"issue":"11","key":"10.1016\/j.euroneuro.2022.01.008_bib0047","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/FPC.0b013e328346063f","article-title":"PharmGKB summary: citalopram pharmacokinetics pathway","volume":"21","author":"Sangkuhl","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.01.008_bib0048","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0000000000001080","article-title":"Smoking Is Associated With Lower Dose-Corrected Serum Concentrations of Escitalopram","volume":"39","author":"Scherf-Clavel","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.01.008_bib0049","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1515\/dmdi-2014-0028","article-title":"Pharmacogenetics of drug-metabolizing enzymes in Italian populations","volume":"30","author":"Serpe","year":"2015","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0050","article-title":"A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials","author":"Sforzini","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0051","article-title":"Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy","author":"Song","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0052","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-021-01001-5","article-title":"Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes","author":"Song","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0053","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","article-title":"Clinical applications of CYP genotyping in psychiatry","volume":"122","author":"Spina","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"issue":"16","key":"10.1016\/j.euroneuro.2022.01.008_bib0054","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2217\/pgs-2020-0087","article-title":"Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6\u00d76 and CYP2C19\u00d717 variants: a case report","volume":"21","author":"Stauble","year":"2020","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.01.008_bib0055","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/appi.ajp.2018.18020134","article-title":"Mindful Pharmacogenetics: drug Dosing for Mental Health","volume":"175","author":"Stingl","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.01.008_bib0056","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13396","article-title":"Escitalopram in Adolescents With Generalized Anxiety Disorder: a Double-Blind, Randomized, Placebo-Controlled Study","volume":"81","author":"Strawn","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.01.008_bib0057","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u2013an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.01.008_bib0058","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/YIC.0b013e328330adb2","article-title":"Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression","volume":"25","author":"Thase","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0059","first-page":"27","article-title":"Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective","volume":"139","author":"Umamaheswaran","year":"2014","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0060","series-title":"The Python Language Reference: Release 3.6.4. 12th Media Services","author":"Van Rossum","year":"2018"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.575540","article-title":"Pharmacogenetics in Psychiatry: an Update on Clinical Usability","volume":"11","author":"van Schaik","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0062","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fpsyt.2020.00094","article-title":"Pharmacogenomics of Antidepressant and Antipsychotic Treatment: how Far Have We Got and Where Are We Going?","volume":"11","author":"van Westrhenen","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0063","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.psychres.2018.02.055","article-title":"Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication","volume":"279","author":"Walden","year":"2019","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0064","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/00498254.2019.1648911","article-title":"Cytochrome P450: genotype to phenotype","volume":"50","author":"Waring","year":"2020","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.110.034504","article-title":"Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes","volume":"39","author":"Washio","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0066","series-title":"Mwaskom\/Seaborn: V0. 8.1 (September 2017). Zenodo","author":"Waskom","year":"2017"},{"issue":"4","key":"10.1016\/j.euroneuro.2022.01.008_bib0067","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"D1","key":"10.1016\/j.euroneuro.2022.01.008_bib0068","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic. Acids. Res."},{"issue":"8","key":"10.1016\/j.euroneuro.2022.01.008_bib0069","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjp.0705195","article-title":"Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine","volume":"138","author":"Wojcikowski","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0070","series-title":"Defined Daily Dose (DDD)","year":"2021"},{"issue":"10","key":"10.1016\/j.euroneuro.2022.01.008_bib0071","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/17425255.2019.1669560","article-title":"Pharmacokinetic considerations for current state-of-the-art antidepressants","volume":"15","author":"Wyska","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113470","article-title":"Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients","volume":"293","author":"Yan","year":"2020","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.01.008_bib0073","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1067\/mcp.2001.114231","article-title":"Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19","volume":"69","author":"Yu","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.008_bib0074","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2022.01.008_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.674273","article-title":"Drug response-related DNA methylation changes in schizophrenia, bipolar disorder, and major depressive disorder","volume":"15","author":"Zhou","year":"2021","journal-title":"Front Neurosci"},{"issue":"12","key":"10.1016\/j.euroneuro.2022.01.008_bib0076","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:02:21Z","timestamp":1760378541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X22000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":76,"alternative-id":["S0924977X22000165"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.01.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}